stockrow
Friday 6 November 2026
Export TMDX’s income statement to Excel — free account
TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
85.40
16.42
+23.80%
Follow TMDX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
19.87 | 15.03 | 19.76 | 21.80 |
+8 more quarters Free account |
P/S ratio |
3.98 | 3.44 | 5.38 | 6.83 | |
P/FCF ratio |
64.77 | 29.06 | 22.58 | 30.96 | |
P/Operating CF |
80.41 | 132.69 | 139.33 | 119.82 | |
P/B ratio |
5.26 | 4.43 | 6.92 | 8.74 | |
Price to Tangible BV |
5.37 | 4.53 | 7.08 | 9.00 | |
EV/Sales |
4.53 | 4.02 | 6.00 | 6.87 | |
EV/EBITDA |
26.00 | 22.76 | 29.94 | 30.64 | |
EV/Operating CF |
29.36 | 18.40 | 17.32 | 21.57 | |
EV/FCF |
73.80 | 33.98 | 25.19 | 31.14 | |
Quick Ratio |
3.98 | 5.87 | 6.01 | 6.41 | |
Current Ratio |
4.53 | 6.63 | 6.74 | 7.14 | |
Net Debt/EBITDA |
(11.24) | 11.45 | 15.71 | 0.84 | |
Debt/Assets |
3.61% | 58.84% | 59.73% | 47.96% | |
Debt/Equity |
0.10 | 1.66 | 1.73 | 1.08 | |
Asset Turnover |
0.59 | 0.57 | 0.56 | 0.65 | |
Operating CF/Net income |
2.11 | 1.18 | 3.35 | 0.33 | |
Capex/Depreciation |
(0.77) | (0.69) | (3.09) | (2.08) | |
Interest Coverage |
3.87 | 3.29 | 1.85 | 6.34 | |
Research and Development Expense of Revenue |
14.38% | 16.65% | 14.30% | 12.88% | |
Selling, General and Administrative Expense of Revenue |
30.21% | 30.45% | 36.21% | 32.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
6.21% | 4.53% | 5.72% | 5.84% | |
Graham Net Nets |
(0.09) | (0.13) | (0.09) | 0.01 | |
Graham Number |
38.73 | 38.60 | 40.32 | 41.80 | |
Earnings Yield |
5.03% | 6.65% | 5.06% | 4.59% | |
Free Cash Flow Yield |
1.54% | 3.44% | 4.43% | 3.23% | |
Revenue per Share |
5.85 | 5.49 | 5.06 | 4.73 | |
Operating CF per Share |
1.04 | 0.50 | 0.71 | 1.02 | |
Capex per Share |
(0.24) | (0.21) | (1.07) | (0.46) | |
Free Cash Flow per Share |
0.80 | 0.30 | (0.35) | 0.56 | |
Cash per Share |
14.21 | 13.67 | 13.43 | 14.37 | |
Shareholders Equity per Share |
15.87 | 14.98 | 14.37 | 13.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.87 | 14.98 | 14.37 | 13.92 | |
Free Cash Flow |
27.60 | 10.22 | (12.12) | 19.00 | |
Working Capital |
539.60 | 552.84 | 527.36 | 548.48 | |
Capital Expenditures |
(8.40) | (7.09) | (36.66) | (15.51) | |
Net Current Asset Value |
(274.77) | (295.22) | (321.53) | 42.51 | |
EV/EBIT |
38.16 | 32.91 | 40.38 | 38.31 | |
Capex to Sales |
0.04 | 0.04 | 0.21 | 0.10 | |
Price to Operating Income |
33.49 | 28.15 | 36.19 | 38.08 | |
| Other line items | |||||
Average Receivables |
97.82 | 104.49 | 116.38 | 91.00 | |
Average Payables |
11.15 | 11.22 | 10.87 | 10.32 | |
Average Inventory |
51.44 | 46.50 | 46.64 | 47.72 | |
Average Assets |
1,231.98 | 1,177.46 | 1,136.18 | 936.22 | |
Average Common Equity |
452.96 | 418.08 | 380.16 | 350.85 |
Columns are period end dates · fundamentals updated 5 Nov 2026